US Pharma MarketingApnimed raises $192M IPO for potential 2027 sleep apnea drug launch
In the city that never sleeps, a sleep apnea drug developer has secured a $192 million IPO after more than three years of eyeing a Nasdaq debut. Apnimed is slated to begin ...
In the city that never sleeps, a sleep apnea drug developer has secured a $192 million IPO after more than three years of eyeing a Nasdaq debut.
Apnimed is slated to begin ...
Source: Endpoints News